Skip to main content
Off-label uses of TNFa inhibitors and IL12/23 inhibitors in dermatology
- Hong, Julie J;
- Hadeler, Edward K;
- Mosca, Megan L;
- Brownstone, Nicholas D;
- Bhutani, Tina;
- Liao, Wilson J
© 2021 by the author(s). Learn more.
Published Web Locationhttps://doi.org/10.5070/D3271156085
TNFa inhibitors, which include adalimumab, infliximab, etanercept, certolizumab, and golimumab, and IL12/23 inhibitor, ustekinumab, have been widely used as a U.S. Food and Drug Administration (FDA) approved for the treatment of psoriasis. Outside of psoriasis, high levels of TNFa had also been found in several skin diseases including hidradenitis suppurativa. IL12 and IL23 play important role in the pathogenesis of SLE, alopecia areata, and vitiligo. This paper reviews the off-label uses of TNFa inhibitors and IL12/23 inhibitors in skin disorders.
For improved accessibility of PDF content, download the file to your device.
Enter the password to open this PDF file:
Fast Web View:
Preparing document for printing…